Experience of Long-Term Use of Afala in Benign Prostatic Hyperplasia

Simple item page
dc.creatorGulamov, M. X.
dc.date2023-04-29
dc.date.accessioned2023-08-21T09:04:45Z
dc.date.available2023-08-21T09:04:45Z
dc.descriptionThe use of ultra-low doses of antibodies to the prostate-specific antigen (afala) for long-term treatment of benign prostatic hypertrophy in patients with moderately severe symptoms can quickly and effectively reduce irritative and obstructive symptoms, significantly reduce the volume of residual urine, and increase the speed of urination. Afala therapy is indicated for patients with stage I-II benign prostatic hyperplasia with moderately severe symptoms.en-US
dc.formatapplication/pdf
dc.identifierhttps://univerpubl.com/index.php/scholastic/article/view/1317
dc.identifier.urihttp://dspace.umsida.ac.id/handle/123456789/21986
dc.languageeng
dc.publisherUniver Publishingen-US
dc.relationhttps://univerpubl.com/index.php/scholastic/article/view/1317/1138
dc.sourceScholastic: Journal of Natural and Medical Education; Vol. 2 No. 4 (2023): Scholastic: Journal of Natural and Medical Education; 283-286en-US
dc.subjectprostate adenomaen-US
dc.subjectbenign prostatic hyperplasiaen-US
dc.subjectafalaen-US
dc.titleExperience of Long-Term Use of Afala in Benign Prostatic Hyperplasiaen-US
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typePeer-reviewed Articleen-US
Files
Collections
Scholastic: Journal of Natural and Medical Education